Description
FABRX provides pharmaceutical 3D printers, bespoke software and formulation development services for the pharmaceutical 3D printing of medicines for personalised medicine, automated compounding and clinical trial batch manufacture.
FABRX's cofounders have been listed as the top two world experts in the field by Expertscape and are highly cited researchers for 5 years in a row (Clarivate). They have carried out the most clinical studies in the field, including the first in 2018 and now involved in over 8 worldwide.
What we offer
FABRX launched the worlds first pharmaceutical 3D printer for small batch manufacture in 2020. As first movers, they are the only company in the field with in-built quality control technology (a balance and near infrared spectrometer) in printers, allowing for automated, inline quality assurance. They also have an exchangeable printhead system, allowing for easy cleaning and technology versatility, currently offer semi-sold extrusion, direct powder extrusion, fused deposition modelling and a pellet dispenser. The newly launched software packages have unique capabilities to allow for easy to use, quality assured printing in clinical sites, allowing for off site auditing, quality checking and protocol library access.
What we look for
FABRX is looking to establish collaboration with a hospital in Florida, with the intention to acquire a 3D printer through direct purchase or a collaborative grant application to carry out a first-in-the-US clinical study. They would like to connect and meet with key hospital decision makers in leading Florida hospitals and pharmaceutical academics in the universities.
Gallery
